As of 2025-03-17, the Relative Valuation of EyePoint Pharmaceuticals Inc (EYPT) is (36.66) USD. This relative valuation is based on P/E multiples. With the latest stock price at 6.52 USD, the upside of EyePoint Pharmaceuticals Inc based on Relative Valuation is -662.2%.
The range of the Relative Valuation is (31.75) - (40.24) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 16.5x - 21.8x | 19.9x |
| Forward P/E multiples | 16.1x - 20.9x | 18.2x |
| Fair Price | (31.75) - (40.24) | (36.66) |
| Upside | -586.9% - -717.2% | -662.2% |
| Date | P/E |
| 2025-03-14 | -3.39 |
| 2025-03-13 | -3.55 |
| 2025-03-12 | -3.81 |
| 2025-03-11 | -3.82 |
| 2025-03-10 | -3.69 |
| 2025-03-07 | -3.71 |
| 2025-03-06 | -3.55 |
| 2025-03-05 | -3.42 |
| 2025-03-04 | -3.16 |
| 2025-03-03 | -2.98 |
| 2025-02-28 | -3.26 |
| 2025-02-27 | -3.24 |
| 2025-02-26 | -3.07 |
| 2025-02-25 | -3.10 |
| 2025-02-24 | -3.08 |
| 2025-02-21 | -3.20 |
| 2025-02-20 | -3.30 |
| 2025-02-19 | -3.37 |
| 2025-02-18 | -3.40 |
| 2025-02-14 | -3.38 |
| 2025-02-13 | -3.28 |
| 2025-02-12 | -3.30 |
| 2025-02-11 | -3.27 |
| 2025-02-10 | -3.26 |
| 2025-02-07 | -3.38 |
| 2025-02-06 | -3.44 |
| 2025-02-05 | -4.06 |
| 2025-02-04 | -3.97 |
| 2025-02-03 | -3.73 |
| 2025-01-31 | -3.98 |
| 2025-01-30 | -4.19 |
| 2025-01-29 | -4.02 |
| 2025-01-28 | -4.07 |
| 2025-01-27 | -4.17 |
| 2025-01-24 | -4.44 |
| 2025-01-23 | -4.59 |
| 2025-01-22 | -4.54 |
| 2025-01-21 | -3.97 |
| 2025-01-17 | -3.89 |
| 2025-01-16 | -3.78 |
| 2025-01-15 | -4.00 |
| 2025-01-14 | -3.75 |
| 2025-01-13 | -4.03 |
| 2025-01-10 | -4.34 |
| 2025-01-08 | -4.74 |
| 2025-01-07 | -4.80 |
| 2025-01-06 | -4.52 |
| 2025-01-03 | -4.30 |
| 2025-01-02 | -4.18 |
| 2024-12-31 | -3.88 |